Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatitis C: therapeutic perspectives.

M Cornberg1, H Wedemeyer, M P Manns

  • 1Department of Gastroenterology and Hepatology, Medical School Hannover, Germany.

Forum (Genoa, Italy)
|April 12, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Droplet Digital PCR: A Powerful Tool for Accurate Quantification of Hepatitis D Virus RNA Levels and Verification of Detection Limits.

Journal of viral hepatitis·2025
Same author

[Strategietreffen: Virushepatitis in Deutschland eliminieren].

Zeitschrift fur Gastroenterologie·2023
Same author

[Erratum to: Sepsis with hemolysis due to a liver abscess in a 60-year-old male patient].

Der Internist·2022
Same author

Zeitschrift fur Gastroenterologie·2022
Same author

Zeitschrift fur Gastroenterologie·2022
Same author

Percutaneous Transsplenic Balloon-Assisted Transjugular Intrahepatic Portosystemic Shunt Placement in Patients with Portal Vein Obliteration for Portal Vein Recanalization: Feasibility, Safety and Effectiveness.

Cardiovascular and interventional radiology·2022
Same journal

The basis of allograft acceptance.

Forum (Genoa, Italy)·2011
Same journal

Recurrent liver disease after liver transplantation.

Forum (Genoa, Italy)·2011
Same journal

Integrated treatments for non-small cell lung cancer.

Forum (Genoa, Italy)·2006
Same journal

Gastrointestinal tumors.

Forum (Genoa, Italy)·2006
Same journal

Primary and metastatic brain tumors.

Forum (Genoa, Italy)·2006
Same journal

Impact of integrated treatments on patient management in solid tumors: from diagnosis to palliative care.

Forum (Genoa, Italy)·2006
See all related articles

Newer pegylated interferon (PEG-IFN) and ribavirin combinations significantly improve hepatitis C virus (HCV) treatment response rates. These advancements offer better outcomes for patients, including those with difficult-to-treat infections.

Area of Science:

  • Hepatology
  • Virology
  • Pharmacology

Background:

  • Standard interferon-alpha (IFN) and ribavirin therapy fails to eliminate the hepatitis C virus (HCV) in over 50% of patients.
  • Developing novel strategies is crucial for improving sustained response rates in difficult-to-treat HCV infections.

Purpose of the Study:

  • To evaluate enhanced treatment options for hepatitis C virus (HCV) infection.
  • To explore the efficacy of modified interferon-based therapies and novel antiviral agents.

Main Methods:

  • Clinical trials assessed modified interferon dosing schedules, including daily IFN, consensus IFN, and pegylated IFN (PEG-IFN).
  • Response rates were compared between standard therapy, PEG-IFN monotherapy, and PEG-IFN combined with ribavirin.
  • Potential future therapies targeting viral proteins and replication mechanisms were discussed.

Related Experiment Videos

Main Results:

  • Pegylated interferon (PEG-IFN) monotherapy doubled response rates compared to standard IFN.
  • The combination of PEG-IFN and ribavirin achieved over 50% virological response, exceeding 80% in patients with HCV genotypes 2 or 3.
  • Consensus IFN showed potential benefits for pre-treated patients and those with HCV genotype-1.

Conclusions:

  • The standard therapy for chronic hepatitis C has evolved to the combination of PEG-IFN plus ribavirin.
  • Future treatments may involve direct-acting antiviral agents targeting HCV proteins and replication, as well as immunotherapies to boost host immune responses.